Rasburicase (SR29142)

DRUG5 trials

Sponsors

Sanofi

Conditions

CancerHyperuricemiaLeukemiaLymphomaNutritional and Metabolic DiseasesTumor Lysis SyndromeTumors

Phase 2

Rasburicase for Hyperuricemia

CompletedNCT00290992

SanofiNutritional and Metabolic Diseases

Start: 2005-06-30End: 2006-04-30Updated: 2009-03-30

Rasburicase as a Uricolytic Therapy for Hyperuricemia in Patients With Leukemia or Lymphoma

CompletedNCT00631579

SanofiHyperuricemia, Leukemia, Lymphoma

Start: 2003-04-30End: 2004-06-30Updated: 2009-10-02

Rasburicase for the Treatment/Prevention of Hyperuricemia in Adult Patients With Relapsing Aggressive Non Hodgkin's Lymphoma

TerminatedNCT00664144

SanofiHyperuricemia

Start: 2002-07-31End: 2005-01-31Updated: 2012-03-07

Phase 3

Rasburicase Versus Allopurinol in Tumor Patients at Risk for Hyperuricemia and Tumor Lysis Syndrome

CompletedNCT00230178

SanofiCancer, Hyperuricemia, Tumor Lysis Syndrome

Start: 2004-04-30End: 2007-12-31Updated: 2010-01-12

Phase 4

Study of Rasburicase as Treatment or Prevention of Hyperuricemia Associated With Tumor Lysis Syndrome in Patients With Relapsed or Refractory Lymphoma, Leukemia, or Solid Tumor Malignancy

CompletedNCT00230217

SanofiHyperuricemia, Tumor Lysis Syndrome, Tumors

Start: 2004-03-31End: 2006-07-31Updated: 2009-03-30